These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prognostic value of plasma myeloperoxidase in ESRD patients. Wang AY; Lam CW; Chan IH; Wang M; Lui SF; Sanderson JE Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167 [TBL] [Abstract][Full Text] [Related]
23. Early therapeutic intervention in females with Fabry disease? Hughes DA Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187 [TBL] [Abstract][Full Text] [Related]
24. Higher frequency of paraoxonase gene polymorphism and cardiovascular impairment among Brazilian Fabry Disease patients. Barris-Oliveira AC; Müller KB; Turaça LT; Pesquero JB; Martins AM; D'Almeida V Clin Biochem; 2012 Nov; 45(16-17):1459-62. PubMed ID: 22796398 [TBL] [Abstract][Full Text] [Related]
25. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529 [TBL] [Abstract][Full Text] [Related]
26. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826 [TBL] [Abstract][Full Text] [Related]
27. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066 [TBL] [Abstract][Full Text] [Related]
29. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease. Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536 [TBL] [Abstract][Full Text] [Related]
30. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study. Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342 [TBL] [Abstract][Full Text] [Related]
32. Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease. Rohard I; Schaefer E; Kampmann C; Beck M; Gal A J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S349-56. PubMed ID: 18941922 [TBL] [Abstract][Full Text] [Related]
33. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP; Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317 [TBL] [Abstract][Full Text] [Related]
34. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects]. Peces R; Olea T Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287 [TBL] [Abstract][Full Text] [Related]
35. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P. Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164 [TBL] [Abstract][Full Text] [Related]
36. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091 [TBL] [Abstract][Full Text] [Related]
37. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006 [TBL] [Abstract][Full Text] [Related]
40. Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. Siegenthaler M; Huynh-Do U; Krayenbuehl P; Pollock E; Widmer U; Debaix H; Olinger E; Frank M; Namdar M; Ruschitzka F; Nowak A Int J Cardiol; 2017 Dec; 249():261-267. PubMed ID: 28964554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]